NASDAQ:LAVA LAVA Therapeutics (LAVA) Stock Price, News & Analysis → The asset beating inflation by 4x (From Colonial Metals) (Ad) Free LAVA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get LAVA Therapeutics alerts: Email Address Ad Behind the MarketsBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ONE stock you should be watching.Get the full story here >>> About LAVA Therapeutics Stock (NASDAQ:LAVA)Magma Design Automation, Inc. (Magma) provides electronic design automation (EDA) software products and related services. Its software enables chip designers to reduce the time it takes to design and produce integrated circuits used in the communications, computing, consumer electronics, networking and semiconductor industries. Its flagship products consist of a digital integrated solution for the chip development cycle, from initial design through physical implementation. Magma’s flagship Talus family of products, its Tekton static timing analyzer and QCP extractor and, its Quartz family of sign-off and verification tools combine into one integrated chip design and verification flow, from what has been separate logic design, physical design, and analysis and sign-off processes. Its Titan platform for custom integrated chip design provides an integrated chip-finishing solution for mixed-signal designs. In February 2012, Synopsys, Inc. acquired the Company.Read More Ad Behind the MarketsBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ONE stock you should be watching.Get the full story here >>> LAVA Stock News HeadlinesMay 29, 2024 | msn.comZelda: Tears Of The Kingdom Goron City LocationMay 21, 2024 | finanznachrichten.deLAVA Therapeutics N.V.: LAVA Provides Business Updates and Reports First Quarter 2024 Financial ResultsJune 18, 2024 | Behind the Markets (Ad)Bigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ONE stock you should be watching.May 21, 2024 | msn.comLVTX Stock Earnings: LAVA Therapeutics Beats EPS, Misses Revenue for Q1 2024March 21, 2024 | markets.businessinsider.comStrong Buy Rating for LAVA Therapeutics on Promising Clinical and Financial OutlookMarch 21, 2024 | uk.finance.yahoo.comLAVA Therapeutics Full Year 2023 Earnings: Revenues DisappointMarch 20, 2024 | investorplace.comLVTX Stock Earnings: LAVA Therapeutics Misses EPS, Misses Revenue for Q4 2023March 17, 2024 | msn.comLiverpool XI vs Manchester United: Starting lineup, confirmed team news, injury latest for FA Cup todayJune 18, 2024 | Behind the Markets (Ad)Bigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ONE stock you should be watching.March 16, 2024 | finance.yahoo.comLVTX Apr 2024 2.500 callMarch 5, 2024 | finance.yahoo.comLAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)February 26, 2024 | seekingalpha.comPRGS, EVER and LVTX are among after hour moversFebruary 2, 2024 | markets.businessinsider.comStrong Buy Rating for LAVA Therapeutics Amid Strategic Partnerships and Promising Clinical AdvancementsJanuary 25, 2024 | msn.comWhy Humana Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionJanuary 25, 2024 | benzinga.comDow Surges Over 100 Points; US GDP Growth Tops EstimatesJanuary 25, 2024 | msn.comWhy Is Cancer Focused LAVA Therapeutics Nano Cap Stock Trading Higher Today?January 15, 2024 | msn.comNew Alzheimer’s Treatment Accelerates Removal of Plaque From The Brain In Clinical TrialsJanuary 13, 2024 | msn.comPsychedelics gave terminal patients relief from their intense anxietyNovember 27, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Genelux Corp. (GNLX), Calliditas Therapeutics (CALT)November 16, 2023 | finanznachrichten.deLAVA Therapeutics N.V.: Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial ResultsNovember 16, 2023 | businesswire.comMemo Therapeutics AG Appoints Erik van den Berg as Chief Executive OfficerNovember 16, 2023 | msn.comLAVA Therapeutics GAAP EPS of -$0.34 beats by $0.14November 16, 2023 | finance.yahoo.comLava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial ResultsNovember 15, 2023 | finance.yahoo.comK36 Therapeutics Announces Appointment of Benjamin Winograd, MD, PhD, as Chief Medical OfficerSeptember 21, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: US Physical Therapy (USPH), Calliditas Therapeutics (CALT)September 18, 2023 | benzinga.comDelveInsight Highlights Major Advances, Transformative Therapies, and 55+ Leading Players Wheeling the Chronic Lymphocytic Leukemia Pipeline LandscapeSeptember 6, 2023 | bizjournals.comPhiladelphia-area life sciences firms have now cut more than 500 jobs since the start of 2022See More Headlines Receive LAVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LAVA Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:LAVA CUSIPN/A CIK1065034 Webwww.magma-da.com Phone+1-408-5657500FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report This page (NASDAQ:LAVA) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | Sponsoredwhy 99.94% won’t make you moneyI believe there's only 5-7 stocks that you should trade in 2024. But here's the catch…because there's alway...Prosper Trading Academy | SponsoredThe Hidden Anchor Investment of the Elite RevealedThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because sav...Colonial Metals | SponsoredWho are Nvidia’s Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LAVA Therapeutics NV Please log in to your account or sign up in order to add this asset to your watchlist. Share LAVA Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.